Evolent Health Q4 2024 Earnings Report
Key Takeaways
Evolent Health reported Q4 2024 revenue of $646.5 million and a net loss of $30.6 million. The company achieved 100% contract retention across top customers and signed contract amendments expected to yield $115 million annual improvement for 2025.
Revenue for Q4 2024 reached $646.5 million, marking a 16.3% increase year-over-year.
Net loss attributable to common shareholders was $30.6 million, resulting in a net loss margin of (4.7)%.
Adjusted EBITDA stood at $22.6 million, with an Adjusted EBITDA margin of 3.5%.
The company secured contract amendments expected to yield $115 million annual improvement for 2025.
Partner contract retention was 100% across top customers
Evolent Health
Evolent Health
Forward Guidance
For Q1 2025, revenue is projected to be between $440 million and $470 million, with adjusted EBITDA expected to be in the range of $31 million to $37 million. For the full year 2025, revenue is expected to range from approximately $2.06 billion to $2.11 billion, and adjusted EBITDA is projected to be between $135 million and $165 million.
Positive Outlook
- Revenue guidance represents a projection of 15%-18% annual growth after adjusting for one-time contract changes in three Performance Suite contracts moving from 2024 to 2025.
- Adjusted EBITDA is expected to be in the range of approximately $135 million to $165 million.
- Company expects to deploy approximately $35 million in cash for capitalized software development during 2025.